Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 297


A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.

Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F, Choy H.

Clin Cancer Res. 2009 Mar 15;15(6):2158-65. doi: 10.1158/1078-0432.CCR-08-0629. Epub 2009 Mar 10.


Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.

Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara CA, Yankelevitz DF, Subbaramaiah K, Pasmantier MW, Dannenberg AJ.

J Clin Oncol. 2003 Jul 15;21(14):2645-50.


The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.

Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, Lo Vullo S, Mansueto G, Bonginelli P, Gattuso D, Gion M.

Cancer J. 2005 May-Jun;11(3):209-16.


A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.

Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, Fossella F, Brown B, Cox JD.

Clin Cancer Res. 2005 May 1;11(9):3342-8.


Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.

Csiki I, Morrow JD, Sandler A, Shyr Y, Oates J, Williams MK, Dang T, Carbone DP, Johnson DH.

Clin Cancer Res. 2005 Sep 15;11(18):6634-40.


Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.

Friedel G, Budach W, Dippon J, Spengler W, Eschmann SM, Pfannenberg C, Al-Kamash F, Walles T, Aebert H, Kyriss T, Veit S, Kimmich M, Bamberg M, Kohlhaeufl M, Steger V, Hehr T.

J Clin Oncol. 2010 Feb 20;28(6):942-8. doi: 10.1200/JCO.2008.21.7810. Epub 2010 Jan 25.


Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.

Pallarés C, Capdevila J, Paredes A, Farré N, Ciria JP, Membrive I, Basterrechea L, Gomez-Segura G, Barnadas A.

Lung Cancer. 2007 Nov;58(2):238-45. Epub 2007 Jul 20.


Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.

Bradley JD, Paulus R, Graham MV, Ettinger DS, Johnstone DW, Pilepich MV, Machtay M, Komaki R, Atkins J, Curran WJ; Radiation Therapy Oncology Group.

J Clin Oncol. 2005 May 20;23(15):3480-7.


Phase II study of concurrent chemoradiotherapy for inoperable (bulky) stage III (A/B) non-small cell lung cancer (NSCLC): a preliminary report.

Ratanatharathorn V, Lorvidhaya V, Kraipiboon P, Sirachainan E, Maoleekoonpairoj S, Phromratanapongse P, Cheirsilpa A, Tangkaratt S, Srimuninnimit V, Pattaranutaporn P, Lertsanguansinchai P.

J Med Assoc Thai. 2000 Jan;83(1):85-92.


Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.

Timotheadou E, Skarlos DV, Samantas E, Papadopoulos S, Murray S, Skrickova J, Christodoulou C, Papakostantinou C, Pectasides D, Papakostas P, Kaplanova J, Vrettou E, Karina M, Kosmidis P, Fountzilas G.

Anticancer Res. 2007 Nov-Dec;27(6C):4481-9.


Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

McKeage MJ, Reck M, Jameson MB, Rosenthal MA, Gibbs D, Mainwaring PN, Freitag L, Sullivan R, Von Pawel J.

Lung Cancer. 2009 Aug;65(2):192-7. doi: 10.1016/j.lungcan.2009.03.027. Epub 2009 May 5.


[Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].

Mito A, Yamasaki M, Matsuura K, Kajihara T, Nitta T, Awaya H, Arita K, Kashiwado K, Ohashi N.

Gan To Kagaku Ryoho. 2009 Oct;36(10):1653-6. Japanese.


Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.

Tell R, Sederholm C, Klintenberg C, Franksson L, Brandén E, Hillerdal G, Lönn U, Lindén CJ, Ewers SB, Lamberg K, Mrazek E, Lödén B, Sjögren A, Linné T, Friesland S, Sirzén F.

Anticancer Res. 2008 Sep-Oct;28(5B):2851-7.


Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer.

Edelman MJ, Burrows W, Krasna MJ, Bedor M, Smith R, Suntharalingam M.

Lung Cancer. 2010 Apr;68(1):84-8. doi: 10.1016/j.lungcan.2009.05.003. Epub 2009 Jun 21.


Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non-small-cell lung cancer.

Iranzo V, Bremnes RM, Almendros P, Gavilá J, Blasco A, Sirera R, Camps C.

Lung Cancer. 2009 Jan;63(1):63-7. doi: 10.1016/j.lungcan.2008.04.016. Epub 2008 Jun 11.


Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.

Blumenschein GR Jr, Khuri FR, von Pawel J, Gatzemeier U, Miller WH Jr, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A.

J Clin Oncol. 2008 Apr 10;26(11):1879-85. doi: 10.1200/JCO.2007.12.2689.


Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer.

DeCamp MM, Rice TW, Adelstein DJ, Chidel MA, Rybicki LA, Murthy SC, Blackstone EH.

J Thorac Cardiovasc Surg. 2003 Jul;126(1):17-27.


Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer.

Arúajo AM, Mendez JC, Coelho AL, Sousa B, Barata F, Figueiredo A, Amaro T, Azevedo I, Soares M.

Cancer Invest. 2009 May;27(4):391-6. doi: 10.1080/07357900802232756.


Supplemental Content

Support Center